{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T15:23:33Z","timestamp":1785338613461,"version":"3.55.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,3,17]],"date-time":"2021-03-17T00:00:00Z","timestamp":1615939200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,3,17]],"date-time":"2021-03-17T00:00:00Z","timestamp":1615939200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["16K10149"],"award-info":[{"award-number":["16K10149"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["20K08667"],"award-info":[{"award-number":["20K08667"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      While molecularly targeted therapies and immune checkpoint inhibitors have improved the prognosis of advanced melanoma, biomarkers are required to monitor drug responses. Circulating tumor cells (CTCs) are released from primary and\/or metastatic tumors into the peripheral blood. We examined whether CTCs have potential as biomarkers by checking the number of CTCs, as well as the\n                      <jats:italic>BRAF<\/jats:italic>\n                      genotype of individual CTCs, in melanoma patients undergoing BRAF\/MEK inhibitor treatment.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      CTCs were isolated from peripheral blood using a high-density dielectrophoretic microwell array, followed by labeling with melanoma-specific markers (MART-1 and\/or gp100) and a leukocyte marker (CD45). The numbers of CTCs were analyzed in fifteen patients with stage 0\u2013III melanoma. Furthermore, changes in CTC numbers were assessed in five patients with stage IV melanoma at four time points during BRAF\/MEK inhibitor treatment, and the\n                      <jats:italic>BRAF<\/jats:italic>\n                      genotype was analyzed in CTCs isolated from one patient.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      We examined CTCs in patients with stage 0\u2013III (five samples per stage: stage 0\u2013I, stage II, and stage III), and detected CTCs even in patients with early disease (stage 0 and I). Interestingly, recurrence occurred in the lymph nodes of one stage I patient 2 years after the detection of a high number of CTCs in the patient\u2019s blood. The total number of CTCs in four of five patients with stage IV melanoma fluctuated in response to BRAF\/MEK inhibitor treatment, suggesting that CTC number has potential for use as a drug response marker in advanced disease patients. Interestingly, one of those patients had CTCs harboring seven different\n                      <jats:italic>BRAF<\/jats:italic>\n                      genotypes, and the mutated CTCs disappeared upon BRAF\/MEK inhibitor treatment, except for those harboring\n                      <jats:italic>BRAF<\/jats:italic>\n                      <jats:sup>A598V<\/jats:sup>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      CTCs are present even in the early stage of melanoma, and the number of CTCs seems to reflect patients\u2019 responses to BRAF\/MEK inhibitor treatment. Furthermore, genetic heterogeneity of\n                      <jats:italic>BRAF<\/jats:italic>\n                      may contribute to resistance to BRAF\/MEK inhibitors. Our findings demonstrate the usefulness of CTC analysis for monitoring responses to targeted therapies in melanoma patients, and for understanding the mechanism of drug resistance.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12885-021-08016-y","type":"journal-article","created":{"date-parts":[[2021,3,17]],"date-time":"2021-03-17T07:03:01Z","timestamp":1615964581000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Usefulness of monitoring circulating tumor cells as a therapeutic biomarker in melanoma with BRAF mutation"],"prefix":"10.1186","volume":"21","author":[{"given":"Yukiko","family":"Kiniwa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenta","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asuka","family":"Mikoshiba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsuko","family":"Ashida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuyuki","family":"Akiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Morimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4360-6865","authenticated-orcid":false,"given":"Ryuhei","family":"Okuyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,3,17]]},"reference":[{"issue":"11","key":"8016_CR1","doi-asserted-by":"publisher","first-page":"e1197","DOI":"10.1634\/theoncologist.2018-0876","volume":"24","author":"JJ Luke","year":"2019","unstructured":"Luke JJ. Comprehensive clinical trial data summation for BRAF-MEK inhibition and checkpoint immunotherapy in metastatic melanoma. Oncologist. 2019;24(11):e1197\u2013e211. https:\/\/doi.org\/10.1634\/theoncologist.2018-0876.","journal-title":"Oncologist."},{"issue":"25","key":"8016_CR2","doi-asserted-by":"publisher","first-page":"2933","DOI":"10.2217\/fon-2018-0964","volume":"15","author":"JJ Luke","year":"2019","unstructured":"Luke JJ, Ghate SR, Kish J, Lee CH, McAllister L, Mehta S, Ndife B, Feinberg BA. Targeted agents or immuno-oncology therapies as first-line therapy for BRAF-mutated metastatic melanoma: a real-world study. Future Oncol. 2019;15(25):2933\u201342. https:\/\/doi.org\/10.2217\/fon-2018-0964.","journal-title":"Future Oncol"},{"issue":"6","key":"8016_CR3","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1016\/j.tranon.2017.09.007","volume":"10","author":"TM Grzywa","year":"2017","unstructured":"Grzywa TM, Paskal W, Wlodarski PK. Intratumor and Intertumor heterogeneity in melanoma. Transl Oncol. 2017;10(6):956\u201375. https:\/\/doi.org\/10.1016\/j.tranon.2017.09.007.","journal-title":"Transl Oncol"},{"issue":"7","key":"8016_CR4","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1056\/NEJMoa1904059","volume":"381","author":"C Robert","year":"2019","unstructured":"Robert C, Grob JJ, Stroyakovskiy D, Karaszewska B, Hauschild A, Levchenko E, Chiarion Sileni V, Schachter J, Garbe C, Bondarenko I, Gogas H, Mandal\u00e1 M, Haanen JBAG, Lebb\u00e9 C, Mackiewicz A, Rutkowski P, Nathan PD, Ribas A, Davies MA, Flaherty KT, Burgess P, Tan M, Gasal E, Voi M, Schadendorf D, Long GV. Five-year outcomes with Dabrafenib plus Trametinib in metastatic melanoma. N Engl J Med. 2019;381(7):626\u201336. https:\/\/doi.org\/10.1056\/NEJMoa1904059.","journal-title":"N Engl J Med"},{"issue":"12","key":"8016_CR5","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.2340\/00015555-3279","volume":"99","author":"A Ashida","year":"2019","unstructured":"Ashida A, Sakaizawa K, Mikoshiba A, Kiniwa Y, Okuyama R. Circulating tumour DNA reflects tumour burden independently of adverse events caused by systemic therapies for melanoma. Acta Derm Venereol. 2019;99(12):1184\u20135. https:\/\/doi.org\/10.2340\/00015555-3279.","journal-title":"Acta Derm Venereol"},{"issue":"3","key":"8016_CR6","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.jdermsci.2020.01.001","volume":"97","author":"A Mikoshiba","year":"2020","unstructured":"Mikoshiba A, Ashida A, Sakaizawa K, Kiniwa Y, Okuyama R. Detecting copy number alterations of oncogenes in cell-free DNA to monitor treatment response in acral and mucosal melanoma. J Dermatol Sci. 2020;97(3):172\u20138. https:\/\/doi.org\/10.1016\/j.jdermsci.2020.01.001.","journal-title":"J Dermatol Sci"},{"issue":"4","key":"8016_CR7","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1093\/annonc\/mdz046","volume":"30","author":"BT Li","year":"2019","unstructured":"Li BT, Janku F, Jung B, Hou C, Madwani K, Alden R, Razavi P, Reis-Filho JS, Shen R, Isbell JM, Blocker AW, Eattock N, Gnerre S, Satya RV, Xu H, Zhao C, Hall MP, Hu Y, Sehnert AJ, Brown D, Ladanyi M, Rudin CM, Hunkapiller N, Feeney N, Mills GB, Paweletz CP, Janne PA, Solit DB, Riely GJ, Aravanis A, Oxnard GR. Ultra-deep next-generation sequencing of plasma cell-free DNA in patients with advanced lung cancers: results from the actionable genome consortium. Ann Oncol. 2019;30(4):597\u2013603. https:\/\/doi.org\/10.1093\/annonc\/mdz046.","journal-title":"Ann Oncol"},{"issue":"10","key":"8016_CR8","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.1038\/s41591-019-0593-1","volume":"25","author":"F Chemi","year":"2019","unstructured":"Chemi F, Rothwell DG, McGranahan N, Gulati S, Abbosh C, Pearce SP, et al. Pulmonary venous circulating tumor cell dissemination before tumor resection and disease relapse. Nat Med. 2019;25(10):1534\u20139. https:\/\/doi.org\/10.1038\/s41591-019-0593-1.","journal-title":"Nat Med"},{"issue":"40","key":"8016_CR9","doi-asserted-by":"publisher","first-page":"67355","DOI":"10.18632\/oncotarget.18641","volume":"8","author":"CA Aya-Bonilla","year":"2017","unstructured":"Aya-Bonilla CA, Marsavela G, Freeman JB, Lomma C, Frank MH, Khattak MA, Meniawy TM, Millward M, Warkiani ME, Gray ES, Ziman M. Isolation and detection of circulating tumour cells from metastatic melanoma patients using a slanted spiral microfluidic device. Oncotarget. 2017;8(40):67355\u201368. https:\/\/doi.org\/10.18632\/oncotarget.18641.","journal-title":"Oncotarget."},{"issue":"6","key":"8016_CR10","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1038\/jid.2012.468","volume":"133","author":"L Khoja","year":"2013","unstructured":"Khoja L, Lorigan P, Zhou C, Lancashire M, Booth J, Cummings J, Califano R, Clack G, Hughes A, Dive C. Biomarker utility of circulating tumor cells in metastatic cutaneous melanoma. J Invest Dermatol. 2013;133(6):1582\u201390. https:\/\/doi.org\/10.1038\/jid.2012.468.","journal-title":"J Invest Dermatol."},{"issue":"1","key":"8016_CR11","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1097\/CMR.0000000000000025","volume":"24","author":"L Khoja","year":"2014","unstructured":"Khoja L, Shenjere P, Hodgson C, Hodgetts J, Clack G, Hughes A, Lorigan P, Dive C. Prevalence and heterogeneity of circulating tumour cells in metastatic cutaneous melanoma. Melanoma Res. 2014;24(1):40\u20136. https:\/\/doi.org\/10.1097\/CMR.0000000000000025.","journal-title":"Melanoma Res"},{"issue":"8","key":"8016_CR12","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1038\/jid.2015.127","volume":"135","author":"ES Gray","year":"2015","unstructured":"Gray ES, Reid AL, Bowyer S, Calapre L, Siew K, Pearce R, Cowell L, Frank MH, Millward M, Ziman M. Circulating melanoma cell subpopulations: their heterogeneity and differential responses to treatment. J Invest Dermatol. 2015;135(8):2040\u20138. https:\/\/doi.org\/10.1038\/jid.2015.127.","journal-title":"J Invest Dermatol"},{"issue":"7","key":"8016_CR13","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1038\/s41416-020-0750-9","volume":"122","author":"CA Aya-Bonilla","year":"2020","unstructured":"Aya-Bonilla CA, Morici M, Hong X, McEvoy AC, Sullivan RJ, Freeman J, et al. Detection and prognostic role of heterogeneous populations of melanoma circulating tumour cells. Br J Cancer. 2020;122(7):1059\u201367. https:\/\/doi.org\/10.1038\/s41416-020-0750-9.","journal-title":"Br J Cancer"},{"key":"8016_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.canlet.2018.03.013","volume":"424","author":"G Marsavela","year":"2018","unstructured":"Marsavela G, Aya-Bonilla CA, Warkiani ME, Gray ES, Ziman M. Melanoma circulating tumor cells: benefits and challenges required for clinical application. Cancer Lett. 2018;424:1\u20138. https:\/\/doi.org\/10.1016\/j.canlet.2018.03.013.","journal-title":"Cancer Lett"},{"issue":"10","key":"8016_CR15","doi-asserted-by":"publisher","first-page":"2467","DOI":"10.1073\/pnas.1719264115","volume":"115","author":"X Hong","year":"2018","unstructured":"Hong X, Sullivan RJ, Kalinich M, Kwan TT, Giobbie-Hurder A, Pan S, LiCausi JA, Milner JD, Nieman LT, Wittner BS, Ho U, Chen T, Kapur R, Lawrence DP, Flaherty KT, Sequist LV, Ramaswamy S, Miyamoto DT, Lawrence M, Toner M, Isselbacher KJ, Maheswaran S, Haber DA. Molecular signatures of circulating melanoma cells for monitoring early response to immune checkpoint therapy. Proc Natl Acad Sci U S A. 2018;115(10):2467\u201372. https:\/\/doi.org\/10.1073\/pnas.1719264115.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"8016_CR16","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.jdermsci.2018.01.011","volume":"90","author":"Y Kiniwa","year":"2018","unstructured":"Kiniwa Y, Nakamura K, Mikoshiba A, Akiyama Y, Morimoto A, Okuyama R. Diversity of circulating tumor cells in peripheral blood: detection of heterogeneous BRAF mutations in a patient with advanced melanoma by single-cell analysis. J Dermatol Sci. 2018;90(2):211\u20133. https:\/\/doi.org\/10.1016\/j.jdermsci.2018.01.011.","journal-title":"J Dermatol Sci"},{"issue":"8","key":"8016_CR17","doi-asserted-by":"publisher","first-page":"1886","DOI":"10.1158\/1078-0432.CCR-19-2670","volume":"26","author":"A Lucci","year":"2020","unstructured":"Lucci A, Hall CS, Patel SP, Narendran B, Bauldry JB, Royal RE, Karhade M, Upshaw JR, Wargo JA, Glitza IC, Wong MKK, Amaria RN, Tawbi HA, Diab A, Davies MA, Gershenwald JE, Lee JE, Hwu P, Ross MI. Circulating tumor cells and early relapse in node-positive melanoma. Clin Cancer Res. 2020;26(8):1886\u201395. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-2670.","journal-title":"Clin Cancer Res"},{"issue":"6","key":"8016_CR18","doi-asserted-by":"publisher","first-page":"e0130418","DOI":"10.1371\/journal.pone.0130418","volume":"10","author":"A Morimoto","year":"2015","unstructured":"Morimoto A, Mogami T, Watanabe M, Iijima K, Akiyama Y, Katayama K, Futami T, Yamamoto N, Sawada T, Koizumi F, Koh Y. High-density Dielectrophoretic microwell Array for detection, capture, and single-cell analysis of rare tumor cells in peripheral blood. PLoS One. 2015;10(6):e0130418. https:\/\/doi.org\/10.1371\/journal.pone.0130418.","journal-title":"PLoS One"},{"issue":"3","key":"8016_CR19","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.jdermsci.2012.03.005","volume":"66","author":"A Ashida","year":"2012","unstructured":"Ashida A, Uhara H, Kiniwa Y, Oguchi M, Murata H, Goto Y, Uchiyama A, Ogawa E, Hayashi K, Koga H, Okuyama R. Assessment of BRAF and KIT mutations in Japanese melanoma patients. J Dermatol Sci. 2012;66(3):240\u20132. https:\/\/doi.org\/10.1016\/j.jdermsci.2012.03.005.","journal-title":"J Dermatol Sci"},{"issue":"3","key":"8016_CR20","doi-asserted-by":"publisher","first-page":"278","DOI":"10.3892\/mco.2020.1973","volume":"12","author":"H Ichimura","year":"2020","unstructured":"Ichimura H, Nawa T, Yamamoto Y, Shimizu K, Kobayashi K, Kitazawa S, Kanbara H, Odagiri T, Endo K, Matsunaga T, Nakamura S, Yagi S, Sato Y. Detection of circulating tumor cells in patients with lung cancer using metallic micro-cavity array filter: a pilot study. Mol Clin Oncol. 2020;12(3):278\u201383. https:\/\/doi.org\/10.3892\/mco.2020.1973.","journal-title":"Mol Clin Oncol"},{"issue":"1","key":"8016_CR21","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1186\/s13104-015-1420-5","volume":"8","author":"MF Bande","year":"2015","unstructured":"Bande MF, Santiago M, Muinelo-Romay L, Blanco MJ, Mera P, Capeans C, Pardo M, Pi\u00f1eiro A. Detection of circulating melanoma cells in choroidal melanocytic lesions. BMC Res Notes. 2015;8(1):452. https:\/\/doi.org\/10.1186\/s13104-015-1420-5.","journal-title":"BMC Res Notes"},{"issue":"2","key":"8016_CR22","doi-asserted-by":"publisher","first-page":"pkz026","DOI":"10.1093\/jncics\/pkz026","volume":"3","author":"L Thery","year":"2019","unstructured":"Thery L, Meddis A, Cabel L, Proudhon C, Latouche A, Pierga JY, et al. Circulating Tumor Cells in Early Breast Cancer. JNCI Cancer Spectr. 2019;3(2):pkz026.","journal-title":"JNCI Cancer Spectr"},{"issue":"9574","key":"8016_CR23","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.1016\/S0140-6736(07)60781-8","volume":"369","author":"SA Eccles","year":"2007","unstructured":"Eccles SA, Welch DR. Metastasis: recent discoveries and novel treatment strategies. Lancet. 2007;369(9574):1742\u201357. https:\/\/doi.org\/10.1016\/S0140-6736(07)60781-8.","journal-title":"Lancet."},{"issue":"11","key":"8016_CR24","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1001\/jamadermatol.2016.2668","volume":"152","author":"MJ Bax","year":"2016","unstructured":"Bax MJ, Johnson TM, Harms PW, Schwartz JL, Zhao L, Fullen DR, Chan MP. Detection of occult invasion in melanoma in situ. JAMA Dermatol. 2016;152(11):1201\u20138. https:\/\/doi.org\/10.1001\/jamadermatol.2016.2668.","journal-title":"JAMA Dermatol"},{"issue":"9321","key":"8016_CR25","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1016\/S0140-6736(02)08741-X","volume":"359","author":"M Megahed","year":"2002","unstructured":"Megahed M, Schon M, Selimovic D, Schon MP. Reliability of diagnosis of melanoma in situ. Lancet. 2002;359(9321):1921\u20132. https:\/\/doi.org\/10.1016\/S0140-6736(02)08741-X.","journal-title":"Lancet."},{"issue":"15","key":"8016_CR26","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1016\/j.clinbiochem.2014.12.007","volume":"48","author":"AL Reid","year":"2015","unstructured":"Reid AL, Freeman JB, Millward M, Ziman M, Gray ES. Detection of BRAF-V600E and V600K in melanoma circulating tumour cells by droplet digital PCR. Clin Biochem. 2015;48(15):999\u20131002. https:\/\/doi.org\/10.1016\/j.clinbiochem.2014.12.007.","journal-title":"Clin Biochem"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-021-08016-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12885-021-08016-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-021-08016-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,17]],"date-time":"2021-03-17T07:05:08Z","timestamp":1615964708000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-021-08016-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,17]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["8016"],"URL":"https:\/\/doi.org\/10.1186\/s12885-021-08016-y","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-88937\/v1","asserted-by":"object"}]},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,17]]},"assertion":[{"value":"26 September 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Ethics Committee of the Shinshu University School of Medicine (approval numbers 358, 430, and 634). All patients gave their consent to participate in the research and provided written consent forms.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Y.A. and A.M. are employees of Tosoh. Tosoh has applied for patents related to the dielectrophoretic microwell array system. This does not alter the authors\u2019 adherence to all the policies of <i>BMC Cancer<\/i> on sharing data and materials.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"287"}}